Clinical trials
Completed trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
5,909 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 11 |
| 2001 | 13 |
| 2002 | 30 |
| 2003 | 56 |
| 2004 | 105 |
| 2005 | 103 |
| 2006 | 181 |
| 2007 | 231 |
| 2008 | 261 |
| 2009 | 301 |
| 2010 | 316 |
| 2011 | 350 |
| 2012 | 379 |
| 2013 | 338 |
| 2014 | 365 |
| 2015 | 356 |
| 2016 | 368 |
| 2017 | 389 |
| 2018 | 303 |
| 2019 | 308 |
| 2020 | 281 |
| 2021 | 282 |
| 2022 | 182 |
| 2023 | 163 |
| 2024 | 98 |
| 2025 | 40 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5,909 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 306 |
| Novartis Pharmaceuticals | 278 |
| Pfizer | 250 |
| Eli Lilly and Company | 232 |
| Boehringer Ingelheim | 227 |
| GlaxoSmithKline | 224 |
| Bayer | 220 |
| Astellas Pharma Inc | 205 |
| Takeda | 197 |
| Novo Nordisk A/S | 187 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 325 |
| Neoplasms | 178 |
| Carcinoma, Non-Small-Cell Lung | 148 |
| Diabetes Mellitus | 144 |
| Breast Neoplasms | 123 |
| Arthritis, Rheumatoid | 116 |
| Asthma | 96 |
| Hypertension | 96 |
| Pulmonary Disease, Chronic Obstructive | 89 |
| Stomach Neoplasms | 89 |
Trials
Showing 1 to 25 of 5,909. Each trial links to its page on Pharma Observatory.
5,809 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.